A phase I trial of two formulations of TKM HBV in healthy volunteers as a potential therapy for hepatitis B
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2016
Price : $35 *
At a glance
- Drugs ARB 1467 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Arbutus Biopharma
- 10 Jan 2016 Final results of this trial are expected in 1H16, as per Arbutus media release.
- 10 Jan 2016 Status changed from recruiting to completed as per Arbutus media release.
- 05 Aug 2015 According to an Arbutus Biopharma media release, the results from this trial are expected in the second half of 2015.